Thorne HealthTech, Inc. (NASDAQ: THRN), saw its shares enjoy slight gains, on throwing in its lot with Fullscript, the leading care delivery platform for integrative medicine. Fullscript practitioners will now be able to order and recommend Thorne's industry-leading products, ultimately supporting the health and well-being of their patients.
Every Thorne product is developed from extensive clinical research and medical literature that substantiates the presence of each ingredient in their formulas. This research not only confirms every product's efficacy but improves Thorne's understanding of the outcomes allowing for new discoveries.
Additionally, Thorne is the only supplement manufacturer that collaborates with Mayo Clinic on wellness research and content and is trusted by more than four million customers and 45,000 health professionals.
"With health and wellness at the center of conversation now more than ever, we are constantly empowering individuals to take charge of their health through testing, teaching and transforming," said Paul Jacobson, CEO of Thorne HealthTech.
"It's great that Fullscript practitioners will now have access to our high-quality, premium products to help optimize their patient's health and wellness goals."
Fullscript practitioners and patients can now access hundreds of nutritional supplements such as Meriva-500 SF which supports a healthy inflammatory response, NiaCel 400 which contains an exclusive form of nicotinamide riboside (NR), and Basic Nutrients 2/Day, a daily multivitamin.
A webinar explaining the significance of the announcement will be held next Thursday, April 28, hosted by officials from both companies.
Thorne shares gathered 15 cents, or 2.1%, to $7.32.
Related Stories
